Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Multiple randomised, placebo-controlled trials have tested GLP-1 drugs as add-on therapy to insulin in people with T1D, and the picture that emerges is consistent, if modest: meaningful weight loss, real reductions in daily insulin needs, and improvements in CGM time in range
Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
doi: 10.1002/ijc.35286 203 YaoNLiWXuGDuanNYuGQuJ
Learn more about what COFEPRIS found in our report
US$ 24.41
US$ 29.03
US$ 22.63
US$ 24.47
